Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis

European Respiratory Journal

Volumn 43, Issue 5, 2014, Pages 1519-1522

  Soobratty, Mohammad Roshan ^a   Whitfield, Ruth ^a   Subramaniam, Krithika ^b   Grove, Grace ^c   Carver, Anthony ^c   O'Donovan, Grace V ^b   Wu, Houdini H T ^d   Lee, Oona Y C ^d   Swaminathan, Ramasamyiyer ^b,c   Cope, Graham F ^d   Milburn, Heather J ^b,c  

^a MAYDAY UNIVERSITY HOSPITAL   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARYLAMINE ACETYLTRANSFERASE; ISONIAZID; TUBERCULOSTATIC AGENT;

ADULT; BLOOD SAMPLING; CLINICAL ASSESSMENT TOOL; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENOTYPE; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAT2 GENE; PATIENT COMPLIANCE; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SINGLE NUCLEOTIDE POLYMORPHISM; TUBERCULOSIS; TUBERCULOSIS RAPID TEST; URINALYSIS; URINE COLOR; ADOLESCENT; AGED; ALLELE; COLORIMETRY; HOSPITAL INFORMATION SYSTEM; MIDDLE AGED; PROCEDURES; PROSPECTIVE STUDY; TIME; URINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALLELES; ANTITUBERCULAR AGENTS; COLORIMETRY; FEMALE; GENOTYPE; HUMANS; ISONIAZID; MALE; MEDICATION ADHERENCE; MIDDLE AGED; POINT-OF-CARE SYSTEMS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TIME FACTORS; TUBERCULOSIS; URINALYSIS; YOUNG ADULT;

EID: 84899793233     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00132613     Document Type: Letter

References (10)

1. Marais BJ, van Zyl S, Schaaf HS, et al. Adherence to isoniazid preventive chemotherapy: a prospective communitybased study. Arch Dis Child 2006; 91: 762-765.
2. Whitfield R, Cope GF. Point-of-care test to monitor adherence to anti-tuberculous treatment. Ann Clin Biochem 2004; 41: 411-413.
3. Schraufnagel DE, Stoner R, Whiting E, et al. Testing for isoniazid. An evaluation of the Arkansas method. Chest 1990; 98: 314-316.
4. Guerra RL, Conde MB, Efron A, et al. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid. Respir Med 2010; 104: 754-757.
5. Subramanian K. Determination of acetylation status by genotyping and phenotyping. MSc Dissertation. University College London, London, UK, 2011.
6. Parkin DP, Vandenplas S, Botha FJH, et al. Trimodality of isoniazid elimination: phenotype and genotype in patients with tuberculosis. Am J Respir Crit Care Med 1997; 155: 1717-1722.
7. Doll MA, Hein DW. Comprehensive human NAT2 genotype method using single nucleotide polymorphismspecific polymerase chain reaction primers and fluorogenic probes. Anal Biochem 2001; 288: 106-108.
8. Nicolau I, Tian L, Menzies D, et al. Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients. PLoS One 2012; 7: e45913.
9. Eidus L, Glatthaar E, Hodgkin MM, et al. Comparison of isoniazid phenotyping of black and white patients with emphasis on South African blacks. Int J Clin Pharmacol Biopharm 1979; 17: 311-316.
10. Anitha A, Banerjee M. Arylamine N-acetyltransferase 2 polymorphism in the ethnic populations of South India. Int J Mol Med 2003; 11: 125-131.